Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:06 PM
Ignite Modification Date:
2025-12-24 @ 9:06 PM
NCT ID:
NCT00003104
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically proven intermediate prognostic risk (T1-T2) adenocarcinoma of the prostate
* Previously untreated (except for hormonal therapy)
* PSA levels greater than 10 ng/mL and Gleason scores no greater than 6 OR
* PSA levels no greater than 10 ng/mL and Gleason scores at least 7
* Patients requiring volume reduction of prostate prior to radiotherapy continue to be treated at least 3 months on neoadjuvant hormonal therapy prior to radiation
* No evidence of distant metastases
* No regional lymph node involvement
PATIENT CHARACTERISTICS:
Age:
* Not specified
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* No major medical illness
* No psychosis
* No metallic pelvic prosthesis
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No prior chemotherapy
Endocrine therapy:
* See Disease Characteristics
* Prior neoadjuvant antiandrogen therapy allowed
Radiotherapy:
* No prior radiotherapy
* No prior pelvic irradiation
Surgery:
* No prior radical surgery for carcinoma of the prostate
Healthy Volunteers:
False
Sex:
MALE
Study:
NCT00003104
Study Brief:
Protocol Section:
NCT00003104